Background Currently, little is known regarding the association of metabolic comorbidities and disability among multiple sclerosis (MS) patients. Objectives To evaluate insulin resistance (IR) and metabolic syndrome (MetS) in multiple sclerosis patients and their effect on disease progression and disability. Subjects and methods This case-control study was conducted on 50 MS patients and 25 healthy individuals. They were subjected to clinical evaluation and laboratory assessment for metabolic syndrome and insulin resistance. The homeostasis model assessment (HOMA) was used as a measurement of insulin sensitivity. Disability was evaluated by the Extended Disability Status Scale (EDSS). Results As compared to control group, MS patients had a significantly higher prevalence of metabolic syndrome (22% vs 8%, p = 0.04) and insulin resistance (46% vs 0%, p < 0.001). Patients group had significantly higher systolic blood pressure ( p = 0.005), waist circumference ( p < 0.001), fasting blood sugar ( p < 0.001), insulin level ( p = 0.001), low-density lipoproteins ( p = 0.01), triglycerides ( p = 0.02), HOMA-IR ( p < 0.001), and significantly lower high-density lipoproteins ( p = 0.01). No differences in neurological disability was reported between patients who have MetS ( p = 0.7) or IR ( p = 0.3) and those who do not. Conclusion Insulin resistance and metabolic syndrome are more prevalent among MS patients; however, their association with disability and disease progression is questionable.

中文翻译：

---

胰岛素抵抗和代谢综合征对多发性硬化患者残疾的影响

背景 目前，关于多发性硬化症 (MS) 患者代谢合并症和残疾之间的关联知之甚少。目的 评估多发性硬化患者的胰岛素抵抗 (IR) 和代谢综合征 (MetS) 及其对疾病进展和残疾的影响。受试者和方法 该病例对照研究是对 50 名 MS 患者和 25 名健康个体进行的。他们接受了代谢综合征和胰岛素抵抗的临床评估和实验室评估。稳态模型评估（HOMA）被用作胰岛素敏感性的测量。残疾通过扩展残疾状态量表 (EDSS) 进行评估。结果与对照组相比，MS 患者代谢综合征（22% 对 8%，p = 0.04）和胰岛素抵抗（46% 对 0%，p < 0.001)。患者组收缩压（ p = 0.005）、腰围（ p < 0.001）、空腹血糖（ p < 0.001）、胰岛素水平（ p = 0.001）、低密度脂蛋白（ p = 0.01）、甘油三酯显着升高( p = 0.02)、HOMA-IR ( p < 0.001) 和显着降低的高密度脂蛋白 ( p = 0.01)。在患有 MetS ( p = 0.7) 或 IR ( p = 0.3) 的患者和没有的患者之间，没有报告神经功能障碍的差异。结论 胰岛素抵抗和代谢综合征在 MS 患者中更为普遍；然而，它们与残疾和疾病进展的关联值得怀疑。低密度脂蛋白 (p = 0.01)、甘油三酯 (p = 0.02)、HOMA-IR (p < 0.001) 和显着降低的高密度脂蛋白 (p = 0.01)。在患有 MetS ( p = 0.7) 或 IR ( p = 0.3) 的患者和没有的患者之间，没有报告神经功能障碍的差异。结论 胰岛素抵抗和代谢综合征在 MS 患者中更为普遍；然而，它们与残疾和疾病进展的关联值得怀疑。低密度脂蛋白 (p = 0.01)、甘油三酯 (p = 0.02)、HOMA-IR (p < 0.001) 和显着降低的高密度脂蛋白 (p = 0.01)。在患有 MetS ( p = 0.7) 或 IR ( p = 0.3) 的患者和没有的患者之间，没有报告神经功能障碍的差异。结论 胰岛素抵抗和代谢综合征在 MS 患者中更为普遍；然而，它们与残疾和疾病进展的关联值得怀疑。